Previous 10 | Next 10 |
Rosnilimab, AnaptysBio’s wholly-owned anti-PD-1 agonist antibody, demonstrated favorable safety and tolerability in single and multiple ascending dose healthy volunteer cohorts Robust pharmacokinetic profile, in conjunction with rapid and sustained PD-1 receptor occupancy ...
AnaptysBio (NASDAQ:ANAB): Q3 GAAP EPS of -$0.24 beats by $0.64. Revenue of $20.9M beats by $14.22M. Cash, cash equivalents and investments totaled $389.3 million as of September 30, 2021, compared to $411.2 million as of December 31, 2020, for a decrease of $21.9 million. Pres...
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and GEMINI-1 Phase 3 trial initiated subsequent to FDA end-of-Phase 2 meeting Top-line data from ongoing imsidolimab ACORN Phase 2 trial in moderate-to-severe acne anticipated in H1 2022 and HARP Phase 2 trial...
AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty Partners Sagard to receive AnaptysBio’s 8% royalty on annual global net sales of JEMPERLI (dostarlimab-gxly) below $1 billion, plus certain future regulatory and commercial sales milestones, ...
Imsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4 and week 16 Early reduction of erythema with pustules by 60% at week 1 improved to 94% reduction at week 4 and 98% reduction a...
SAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announc...
Roche (OTCQX:RHHBY +0.2%) said that the FDA approved VENTANA MMR RxDx Panel, a companion diagnostic to help identify patients with solid tumors that are deficient in DNA mismatch repair (MMR) who may be eligible for anti-PD-1 immunotherapy. In the U.S., an estimated 14% of patients with ...
Second FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSK JEMPERLI Was Approved For dMMR Endometrial Cancer in the US and Europe in April 2021 $20MM Milestone Payment Earned by AnaptysBio Upon Second JEMPERLI FDA Approval...
Imsidolimab GPP GEMINI-1 Phase 3 trial anticipated to initiate in Q3 2021 following recent FDA end-of-Phase 2 Meeting Imsidolimab GALLOP GPP Phase 2 trial 16-week data to be orally presented at the EADV Congress on October 2 nd , 2021 Imsidolimab Phase 2 trials ongoing in...
AnaptysBio (ANAB) rose 8.4% after a report that the biotech company received a takeover offer.AnaptysBio is working with an investment bank to solicit interest from other parties after the approach, according to a StreetInsider report.Developing story ... For further details see: A...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...